MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Stigmatizing Attitudes Towards People With PD Using The Parkinson’s Disease Social Stigma Perception Scale (PDSP): A Nationwide Study

    AL. Guerra-Anzaldo, WF. Moguel-Cardin, A. Domínguez-García, AJ. Hernández-Medrano, G. Rivera-Monroy, K. Velázquez-Román, RJ. Baños-Betancourt, C. álvarez-Hernández, DP. Romero-Terán, KI. Sánchez-Ramírez, M. Rodríguez-Violante, A. Cervantes-Arriaga (Mexico City, Mexico)

    Objective: This study aimed to: 1) identify factors associated with stigma towards people living with Parkinson's Disease (PwP), and 2) analyze sociodemographic-based variations in the…
  • 2024 International Congress

    WATCH-PD Qualitative Study: A Mental Model of Coping with Disease Progression

    A. Lerner, J. Mammen, R. Al-Rubayie, M. Kostrzebski, J. Adams (Rochester, USA)

    Objective: To qualitatively evaluate how individuals’ adjust to and cope with symptoms of Parkinson’s disease (PD). Background: The WATCH-PD qualitative study is evaluating meaningful symptoms…
  • 2024 International Congress

    Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease.

    NES. Chtioui, CHR. Duval, DAV. St-Pierre (Montreal, Canada)

    Objective: This study aimed to determine whether people with Parkinson’s disease (PD) with an active lifestyle had increased production of certain microbial metabolites such as…
  • 2024 International Congress

    Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, G. Castilla-Fernández, J. Rocha, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: The EPSILON study aimed to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa/dopa decarboxylase inhibitor (DDCi) in patients with…
  • 2024 International Congress

    AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions

    Y-H. Chang, M. Periñan, A. Noyce (London, United Kingdom)

    Objective: To update on AccessPD's progress, emphasising the growth in patient recruitment, data integration, and the preliminary analysis aimed at advancing Parkinson's disease (PD) research.…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

    M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

    Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…
  • 2024 International Congress

    LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics

    D. Jennings, S. Huntwork-Rodriguez, J. Kluss, S. Ota, S. Dhuria, R. Maciuca, K. Fraser, B. Hersh, Z. Berger, C. Ho, P. Chin (South San Francisco, USA)

    Objective: To evaluate safety and biomarker effects of BIIB122/DNL151 in participants with pathogenic LRRK2 variants diagnosed with Parkinson’s disease (LRRK2-PD). Background: Increased LRRK2 kinase activity…
  • 2024 International Congress

    The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial

    C. Han, Y. Xia, J. Wu, Y. Sun, L. Kou, J. Huang, Q. Wang, E. Xu, H. Yu, Q. Ye, X. Luo, H. Ma, H. Chen, L. Wang, T. Wang (wuhan, China)

    Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…
  • 2024 International Congress

    Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

    D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

    Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…
  • « Previous Page
  • 1
  • …
  • 178
  • 179
  • 180
  • 181
  • 182
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Advanced Search
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley